<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" nameag="viewport"/>
<title>Cardiovascular System</title>
<script src="https://cdn.tailwindcss.com"></script>
<script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
<script src="https://cdn.jsdelivr.net/npm/canvas-confetti@1.6.0/dist/confetti.browser.min.js"></script>
<style>
        /* Custom styles for enhanced aesthetics and responsiveness */
        .option-btn {
            transition: all 0.3s ease;
            box-shadow: 0 2px 4px rgba(0, 0, 0, 0.1);
        }
        .option-btn:hover, .option-btn:active {
            transform: scale(1.02);
            box-shadow: 0 4px 8px rgba(0, 0, 0, 0.2);
        }
        .option-btn.selected {
            background-color: #3b82f6;
            color: white;
        }
        .marked {
            background-color: #fef08a;
        }
        .progress-bar {
            transition: width 0.5s ease-in-out;
            background: linear-gradient(to right, #3b82f6, #22c55e);
            box-shadow: 0 2px 4px rgba(0, 0, 0, 0.2);
            animation: pulse 2s infinite;
        }
        @keyframes pulse {
            0% { opacity: 1; }
            50% { opacity: 0.8; }
            100% { opacity: 1; }
        }
        .question-nav-btn, .result-nav-btn-grid {
            width: 40px;
            height: 40px;
            display: flex;
            align-items: center;
            justify-content: center;
            border-radius: 8px;
            font-size: 16px;
            touch-action: manipulation;
            transition: all 0.2s ease;
        }
        .question-nav-btn:hover, .question-nav-btn:active, .result-nav-btn-grid:hover, .result-nav-btn-grid:active {
            transform: scale(1.05);
        }
        .answered {
            background-color: #22c55e;
            color: white;
        }
        .unanswered {
            background-color: #e5e7eb;
        }
        .marked-nav {
            border: 2px solid #fef08a;
        }
        .video-container, .audio-container {
            display: none;
            position: relative;
        }
        .video-container.active, .audio-container.active {
            display: block;
            animation: fadeIn 0.5s ease-in;
        }
        @keyframes fadeIn {
            from { opacity: 0; }
            to { opacity: 1; }
        }
        .section-transition {
            transition: opacity 0.3s ease;
        }
        .section-transition.hidden {
            opacity: 0;
            pointer-events: none;
        }
        .result-nav {
            display: flex;
            justify-content: space-between;
            align-items: center;
            margin-top: 1rem;
        }
        .result-nav-btn {
            background-color: #4b5563;
            color: white;
            padding: 0.5rem 1rem;
            border-radius: 8px;
            transition: all 0.2s ease;
        }
        .result-nav-btn:hover, .result-nav-btn:active {
            background-color: #374151;
            transform: scale(1.05);
        }
        .result-nav-btn:disabled {
            background-color: #d1d5db;
            cursor: not-allowed;
        }
        .error-message {
            color: #dc2626;
            font-weight: bold;
            margin-top: 1rem;
        }
        /* Mobile-specific adjustments */
        @media (max-width: 640px) {
            .question-nav-btn, .result-nav-btn-grid {
                width: 38px;
                height: 38px;
                font-size: 14px;
            }
            .nav-panel, .results-nav-panel {
                width: 100%;
                max-width: 100%;
                overscroll-behavior: contain;
            }
            .option-btn {
                padding: 12px;
                font-size: 14px;
            }
            .header-text {
                font-size: 1.5rem;
            }
            .subheader-text {
                font-size: 0.875rem;
            }
            .button-group, .result-nav {
                flex-direction: column;
                gap: 0.5rem;
            }
            .result-nav-btn {
                width: 100%;
                text-align: center;
            }
        }
        /* Dark mode styles */
        .dark .bg-gray-100 {
            background-color: #1f2937;
        }
        .dark .bg-white {
            background-color: #374151;
        }
        .dark .text-gray-700 {
            color: #d1d5db;
        }
        .dark .text-gray-800 {
            color: #e5e7eb;
        }
        .dark .bg-gray-200 {
            background-color: #4b5563;
        }
        .dark .border {
            border-color: #4b5563;
        }
        .dark .bg-blue-500 {
            background-color: #2563eb;
        }
        .dark .hover\:bg-blue-600:hover {
            background-color: #1d4ed8;
        }
        .dark .bg-yellow-300 {
            background-color: #b45309;
            color: white;
        }
        .dark .hover\:bg-yellow-400:hover {
            background-color: #92400e;
        }
        .dark .bg-green-500 {
            background-color: #15803d;
        }
        .dark .hover\:bg-green-600:hover {
            background-color: #166534;
        }
        .dark .bg-gray-500 {
            background-color: #4b5563;
        }
        .dark .hover\:bg-gray-600:hover {
            background-color: #374151;
        }
        .dark .result-nav-btn, .dark .result-nav-btn-grid {
            background-color: #2563eb;
        }
        .dark .result-nav-btn:hover, .dark .result-nav-btn:active, .dark .result-nav-btn-grid:hover, .dark .result-nav-btn-grid:active {
            background-color: #1d4ed8;
        }
        .dark .result-nav-btn:disabled, .dark .result-nav-btn-grid:disabled {
            background-color: #4b5563;
        }
        .video-placeholder {
            width: 400px;
            height: 300px;
            background-color: #f0f0f0;
            display: flex;
            align-items: center;
            justify-content: center;
            cursor: pointer;
            margin-top: 10px;
            border-radius: 8px;
            border: 1px solid #ccc;
        }
        .play-icon {
            font-size: 40px;
            color: #007bff;
        }
        .video-loading {
            position: absolute;
            top: 50%;
            left: 50%;
            transform: translate(-50%, -50%);
            border: 4px solid #f3f3f3;
            border-top: 4px solid #3b82f6;
            border-radius: 50%;
            width: 40px;
            height: 40px;
            animation: spin 1s linear infinite;
        }
        @keyframes spin {
            0% { transform: translate(-50%, -50%) rotate(0deg); }
            100% { transform: translate(-50%, -50%) rotate(360deg); }
        }
    </style>

<script>
    // --- GEMINI AUTO-CAPTURE LISTENER ---
    // This function runs immediately after the quiz determines an answer is INCORRECT.
    function captureMistake(questionIndex, questionsData) {
        try {
            const item = questionsData[questionIndex];
            // Use the question text as a unique, stable identifier
            const uniqueId = 'srs_quiz_' + btoa(item.text.substring(0, 50)).replace(/=/g, ''); 

            // 1. Clean and simplify the explanation for storage
            let explanationText = item.explanation || item.correct_answer || "No explanation provided.";
            
            // Strip complex HTML (images, lists) and boilerplate text
            explanationText = explanationText.replace(/<img[^>]*>/g, "[IMAGE]").trim(); // Replace images with placeholder
            explanationText = explanationText.replace(/<p><strong>Ans\. [A-Z]\).*/i, "").trim(); // Remove the repeated Answer line
            explanationText = explanationText.replace(/<p><strong>Educational Objective:<\/strong>.*?<\/p>/gs, "").trim(); // Remove EO block
            explanationText = explanationText.replace(/@dams_new_robot/g, "");
            explanationText = explanationText.replace(/<\/?[^>]+(>|$)/g, " ").trim(); // Final strip of remaining tags

            // 2. Prepare card data
            const cardData = {
                text: item.text,
                answer: item.correct_answer,
                explanation: explanationText.substring(0, 500), // Keep explanations short
                nextReview: 0, // Due immediately
                reviews: 0,
                source: document.title.split('-')[0].trim() || 'Quiz'
            };

            // 3. Save to Local Storage (SRS Bank)
            localStorage.setItem(uniqueId, JSON.stringify(cardData));
            
            console.log(`ðŸ§  Captured Mistake #${questionIndex + 1} from ${document.title}`);

        } catch (e) {
            console.error("SRS Capture Failed:", e);
        }
    }
    // --- END GEMINI AUTO-CAPTURE LISTENER ---
</script>

</head>
<body class="bg-gray-100 font-sans transition-colors duration-300 min-h-screen overflow-y-auto">
<!-- Header Section -->
<header class="bg-blue-600 text-white p-4 shadow-lg">
<div class="container mx-auto">
<h1 class="text-2xl md:text-3xl font-bold header-text">Cardiovascular System</h1>
<p class="mt-2 text-sm md:text-base subheader-text">
                65 Questions | 260 Total Marks | 75 min Duration | ~69.23 sec/question
            </p>
<button class="mt-2 bg-gray-200 text-gray-800 px-3 py-1 rounded-lg hover:bg-gray-300 transition dark:bg-gray-600 dark:text-white" id="theme-toggle">
                Toggle Dark Mode
            </button>
</div>
</header>
<!-- Instructions Section -->
<section class="container mx-auto p-4 md:p-6 section-transition" id="instructions">
<div class="bg-white rounded-lg shadow-md p-5 md:p-8 md:p-5 md:p-8 min-h-screen md:min-h-0 md:rounded-lg md:shadow-md rounded-none shadow-none flex flex-col justify-between">
<h2 class="text-xl font-semibold mb-4">Instructions</h2>
<ul class="list-disc list-inside space-y-2 text-gray-700">
<li>This test contains 65 multiple choice questions.</li>
<li>Each question has only one correct answer.</li>
<li>You will have 75 minutes to complete the test.</li>
<li>Click or tap on an option to select your answer.</li>
<li>Use the "Mark for Review" button to revisit questions.</li>
<li>Navigate using Previous/Next buttons or the Questions Navigation panel.</li>
<li>Click "Submit" to finish and view results.</li>
<li>The test will auto-submit when time runs out.</li>
</ul>
<div class="mt-6 flex space-x-4 button-group md:flex-row flex-col">
<button class="bg-blue-500 text-white px-6 py-2 rounded-lg hover:bg-blue-600 transition" id="start-test">Start Test</button>


</div>
<div class="error-message hidden" id="error-message"></div>
</div>
</section>
<!-- Quiz Section -->
<section class="container mx-auto p-4 md:p-6 hidden section-transition" id="quiz">
<div class="bg-white rounded-lg shadow-md p-5 md:p-8 md:p-5 md:p-8 min-h-screen md:min-h-0 md:rounded-lg md:shadow-md rounded-none shadow-none flex flex-col justify-between">
<!-- Progress Bar -->
<div class="w-full bg-gray-200 rounded-full h-3 mb-4">
<div class="progress-bar h-3 rounded-full" id="progress-bar" style="width: 0%"></div>
</div>
<!-- Question Header -->
<div class="flex flex-col md:flex-row justify-between items-center mb-4">
<h2 class="text-lg font-semibold" id="question-number">Question <span>1</span> of 65</h2>
<p class="text-lg font-semibold mt-2 md:mt-0" id="timer">Time Remaining: <span>00:00</span></p>
</div>
<!-- Question Content -->
<div class="mb-6" id="question-content">
<p class="text-gray-800 mb-4" id="question-text"></p>
<div class="flex flex-wrap gap-4 mb-4" id="question-images"></div>
<div class="space-y-3" id="options"></div>
</div>
<!-- Navigation Buttons -->
<div class="flex flex-col md:flex-row justify-between items-center gap-2 md:gap-4">
<button class="bg-gray-300 text-gray-700 px-4 py-2 rounded-lg hover:bg-gray-400 transition w-full md:w-auto" disabled="" id="previous-btn">Previous</button>
<button class="bg-yellow-300 text-gray-700 px-4 py-2 rounded-lg hover:bg-yellow-400 transition w-full md:w-auto" id="mark-review">Mark for Review</button>
<button class="bg-blue-500 text-white px-4 py-2 rounded-lg hover:bg-blue-600 transition w-full md:w-auto" id="next-btn">Next</button>
<button class="bg-gray-500 text-white px-4 py-2 rounded-lg hover:bg-gray-600 transition w-full md:w-auto" id="nav-toggle">Questions Navigation</button>
<button class="bg-green-500 text-white px-4 py-2 rounded-lg hover:bg-blue-600 transition w-full md:w-auto" id="submit-test">Submit Test</button>
</div>
</div>
</section>
<!-- Results Section -->
<section class="container mx-auto p-4 md:p-6 hidden section-transition" id="results">
<div class="bg-white rounded-lg shadow-md p-5 md:p-8 md:p-5 md:p-8 min-h-screen md:min-h-0 md:rounded-lg md:shadow-md rounded-none shadow-none flex flex-col justify-between">
<h2 class="text-2xl font-semibold mb-4">Cardiovascular System - Results</h2>
<div class="grid grid-cols-1 md:grid-cols-2 gap-4 mb-6">
<p><strong>Correct:</strong> <span id="correct-count">0</span></p>
<p><strong>Wrong:</strong> <span id="wrong-count">0</span></p>
<p><strong>Unanswered:</strong> <span id="unanswered-count">0</span></p>
<p><strong>Marked for Review:</strong> <span id="marked-count">0</span></p>
</div>
<h3 class="text-lg font-semibold mb-4" id="result-question-number">Question <span>1</span> of 65</h3>
<div class="space-y-6" id="results-content"></div>
<div class="result-nav">
<button aria-label="Previous question result" class="result-nav-btn" disabled="" id="prev-result">Previous</button>
<button aria-label="Toggle results navigation panel" class="result-nav-btn" id="results-nav-toggle">Results Navigation</button>
<button aria-label="Next question result" class="result-nav-btn" id="next-result">Next</button>
</div>
<div class="mt-6 flex space-x-4 button-group md:flex-row flex-col">
<button class="bg-blue-500 text-white px-6 py-2 rounded-lg hover:bg-blue-600 transition" id="take-again">Take Again</button>
<button class="bg-gray-500 text-white px-6 py-2 rounded-lg hover:bg-gray-600 transition" id="review-test">Review Test</button>
</div>
</div>
</section>
<!-- Exit Confirmation Modal -->
<div class="fixed inset-0 bg-black bg-opacity-50 flex items-center justify-center hidden" id="exit-modal">
<div class="bg-white rounded-lg p-6 max-w-sm w-full">
<h2 class="text-xl font-semibold mb-4">Leave Test?</h2>
<p class="text-gray-700 mb-4">Your progress will be lost if you leave this page. Are you sure you want to exit?</p>
<div class="flex justify-end space-x-4">
<button class="bg-gray-300 text-gray-700 px-4 py-2 rounded-lg hover:bg-gray-400 transition" id="continue-test">No, Continue</button>
<button class="bg-red-500 text-white px-4 py-2 rounded-lg hover:bg-red-600 transition" id="exit-test">Yes, Exit</button>
</div>
</div>
</div>
<!-- Submit Confirmation Modal -->
<div class="fixed inset-0 bg-black bg-opacity-50 flex items-center justify-center hidden" id="submit-modal">
<div class="bg-white rounded-lg p-6 max-w-sm w-full">
<h2 class="text-xl font-semibold mb-4">Confirm Submission</h2>
<p class="text-gray-700 mb-2">You have attempted <span id="attempted-count">0</span> of 65 questions.</p>
<p class="text-gray-700 mb-4"><span id="unattempted-count">0</span> questions are unattempted.</p>
<div class="flex justify-end space-x-4">
<button class="bg-gray-300 text-gray-700 px-4 py-2 rounded-lg hover:bg-gray-400 transition" id="cancel-submit">Cancel</button>
<button class="bg-green-500 text-white px-4 py-2 rounded-lg hover:bg-green-600 transition" id="confirm-submit">Submit Test</button>
</div>
</div>
</div>
<!-- Quiz Navigation Panel -->
<div class="fixed inset-y-0 right-0 nav-panel bg-white shadow-lg p-4 hidden overflow-y-auto" id="nav-panel">
<h2 class="text-lg font-semibold mb-4">Questions Navigation</h2>
<div class="mb-4">
<select class="w-full p-2 border rounded-lg text-gray-700" id="nav-filter">
<option value="all">All Questions</option>
<option value="answered">Answered</option>
<option value="unanswered">Unanswered</option>
<option value="marked">Marked for Review</option>
</select>
</div>
<div class="grid grid-cols-5 gap-2 md:gap-3" id="nav-grid"></div>
<button class="mt-4 bg-gray-500 text-white px-4 py-2 rounded-lg hover:bg-gray-600 transition w-full" id="close-nav">Close</button>
</div>
<!-- Results Navigation Panel -->
<div class="fixed inset-y-0 right-0 results-nav-panel bg-white shadow-lg p-4 hidden overflow-y-auto" id="results-nav-panel">
<h2 class="text-lg font-semibold mb-4">Results Navigation</h2>
<div class="mb-4">
<select class="w-full p-2 border rounded-lg text-gray-700" id="results-nav-filter">
<option value="all">All Questions</option>
<option value="answered">Answered</option>
<option value="unanswered">Unanswered</option>
<option value="marked">Marked for Review</option>
</select>
</div>
<div class="grid grid-cols-5 gap-2 md:gap-3" id="results-nav-grid"></div>
<button class="mt-4 bg-gray-500 text-white px-4 py-2 rounded-lg hover:bg-gray-600 transition w-full" id="close-results-nav">Close</button>
</div>
<!-- JavaScript Logic -->
<script>
        // Enable debug mode for detailed logging
        const DEBUG_MODE = true;

        // Log debug messages
        function debugLog(message) {
            if (DEBUG_MODE) {
                console.log(`[DEBUG] ${message}`);
            }
        }

        // Initialize questions with error handling
        let questions = [];
        let currentResultQuestion = 0; // State for current question in results
        try {
            debugLog("Attempting to parse questions_json");
            questions = [{"text": "All the following drugs are used for treatment of congestive heart failure except:", "options": [{"label": "A", "text": "Nesiritide", "correct": false}, {"label": "B", "text": "Sacubitril", "correct": false}, {"label": "C", "text": "Trimetazidine", "correct": true}, {"label": "D", "text": "Metoprolol", "correct": false}], "correct_answer": "C. Trimetazidine", "question_images": [], "explanation_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/screenshot-2024-05-08-094413.png"], "explanation": "<p><strong>Ans. C) Trimetazidine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>â€¢ Explanation:</li><li>â€¢ Option A. Nesiritide: Nesiritide is a recombinant B-type natriuretic peptide that has vasodilatory effects and is used in the management of acute decompensated heart failure.</li><li>â€¢ Option A. Nesiritide:</li><li>â€¢ recombinant B-type natriuretic peptide</li><li>â€¢ vasodilatory effects</li><li>â€¢ acute decompensated heart failure.</li><li>â€¢ Option B. Sacubitril: When combined with valsartan (a neprilysin inhibitor and an angiotensin II receptor blocker, respectively), sacubitril is used to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure.</li><li>â€¢ Option B. Sacubitril:</li><li>â€¢ combined with valsartan</li><li>â€¢ neprilysin inhibitor and an angiotensin II receptor blocker,</li><li>â€¢ reduce the risk of cardiovascular death</li><li>â€¢ hospitalization for heart failure in patients</li><li>â€¢ chronic heart</li><li>â€¢ failure.</li><li>â€¢ Option D. Metoprolol: Metoprolol is a beta-blocker that is used in the management of CHF. It reduces myocardial oxygen demand and can improve survival in patients with heart failure.</li><li>â€¢ Option D. Metoprolol:</li><li>â€¢ beta-blocker</li><li>â€¢ CHF.</li><li>â€¢ reduces myocardial oxygen demand</li><li>â€¢ improve survival in patients with heart failure.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>âž¤ Educational Objective:</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Angiotensin receptor blocker which blocks thromboxane A2 receptor is?", "options": [{"label": "A", "text": "Losartan", "correct": true}, {"label": "B", "text": "Telmisartan", "correct": false}, {"label": "C", "text": "Candesartan", "correct": false}, {"label": "D", "text": "Olmesartan", "correct": false}], "correct_answer": "A. Losartan", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. A) Losartan</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>â€¢ Explanation:</li><li>â€¢ Option B. Telmisartan: Incorrect because Telmisartan is known as a partial agonist of peroxisome proliferator-activated receptor gamma (PPAR-Î³), which differentiates it from Losartan and does not confer the ability to block the thromboxane A2 receptor.</li><li>â€¢ Option B. Telmisartan:</li><li>â€¢ Incorrect</li><li>â€¢ Telmisartan is known as a partial agonist of peroxisome proliferator-activated receptor</li><li>â€¢ gamma (PPAR-Î³),</li><li>â€¢ does not</li><li>â€¢ block the thromboxane A2 receptor.</li><li>â€¢ Option C. Candesartan: Incorrect as Candesartan is an inactive ester prodrug that does not possess the ability to block the thromboxane A2 receptor. It is hydrolyzed to its active form within the body, which acts selectively on the angiotensin receptor.</li><li>â€¢ Option C. Candesartan:</li><li>â€¢ Incorrect</li><li>â€¢ Candesartan</li><li>â€¢ inactive ester</li><li>â€¢ does not</li><li>â€¢ block the</li><li>â€¢ thromboxane A2 receptor.</li><li>â€¢ hydrolyzed</li><li>â€¢ its active form</li><li>â€¢ acts selectively</li><li>â€¢ angiotensin receptor.</li><li>â€¢ Option D. Olmesartan: Incorrect for this question since Olmesartan, while also being an inactive ester prodrug hydrolyzed to its active form , does not block the thromboxane A2 receptor. It is cleared by renal elimination and biliary excretion and does not require dose adjustment in patients with mild-to-moderate renal or hepatic impairment.</li><li>â€¢ Option D. Olmesartan:</li><li>â€¢ Incorrect</li><li>â€¢ Olmesartan,</li><li>â€¢ inactive ester prodrug hydrolyzed</li><li>â€¢ active form</li><li>â€¢ does not block the thromboxane A2 receptor.</li><li>â€¢ cleared by renal elimination</li><li>â€¢ biliary excretion</li><li>â€¢ does not</li><li>â€¢ mild-to-moderate renal or hepatic impairment.</li><li>â€¢ Educational objective:</li><li>â€¢ Educational objective:</li><li>â€¢ Losartan is unique among angiotensin receptor blockers in that it also competitively antagonizes the thromboxane A2 receptor, contributing to its antiplatelet effects.</li><li>â€¢ Losartan</li><li>â€¢ angiotensin receptor blockers</li><li>â€¢ competitively antagonizes</li><li>â€¢ thromboxane A2 receptor,</li><li>â€¢ antiplatelet effects.</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A patient is taking atorvastatin for dyslipidemia. Which of these drugs should be avoided in this patient?", "options": [{"label": "A", "text": "Clarithromycin", "correct": true}, {"label": "B", "text": "Oxycodone", "correct": false}, {"label": "C", "text": "Rivaroxaban", "correct": false}, {"label": "D", "text": "Adalimumab", "correct": false}], "correct_answer": "A. Clarithromycin", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. A) Clarithromycin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>â€¢ Explanation:</li><li>â€¢ Option B. Oxycodone: Incorrect because oxycodone, an opioid analgesic, does not significantly interact with the CYP3A4 enzyme in a way that would affect the metabolism of atorvastatin to a clinically relevant extent.</li><li>â€¢ Option B. Oxycodone:</li><li>â€¢ Incorrect</li><li>â€¢ opioid analgesic,</li><li>â€¢ does not</li><li>â€¢ CYP3A4 enzyme</li><li>â€¢ metabolism of atorvastatin to a clinically relevant extent.</li><li>â€¢ Option C. Rivaroxaban: Incorrect as rivaroxaban, an anticoagulant , is not metabolized by CYP3A4 in a way that would interfere with atorvastatin metabolism.</li><li>â€¢ Option C. Rivaroxaban:</li><li>â€¢ Incorrect</li><li>â€¢ rivaroxaban,</li><li>â€¢ anticoagulant</li><li>â€¢ not metabolized by CYP3A4</li><li>â€¢ atorvastatin metabolism.</li><li>â€¢ Option D. Adalimumab: Incorrect because adalimumab , an immunosuppressive drug used to treat autoimmune diseases, does not interact with the CYP3A4 enzyme and thus would not affect atorvastatin levels.</li><li>â€¢ Option D. Adalimumab:</li><li>â€¢ Incorrect</li><li>â€¢ adalimumab</li><li>â€¢ immunosuppressive drug</li><li>â€¢ autoimmune diseases, does not</li><li>â€¢ CYP3A4 enzyme</li><li>â€¢ would not</li><li>â€¢ atorvastatin levels.</li><li>â€¢ Educational objective:</li><li>â€¢ Educational objective:</li><li>â€¢ When prescribing statins, avoid concomitant use with drugs that inhibit CYP3A4, such as clarithromycin, to prevent an increase in their plasma levels which could lead to myopathy. Other notable CYP3A4 inhibitors to avoid include amiodarone, gemfibrozil, HIV protease inhibitors (such as saquinavir, ritonavir), and itraconazole.</li><li>â€¢ statins,</li><li>â€¢ avoid</li><li>â€¢ inhibit CYP3A4,</li><li>â€¢ clarithromycin,</li><li>â€¢ increase</li><li>â€¢ plasma levels</li><li>â€¢ lead to myopathy.</li><li>â€¢ CYP3A4 inhibitors</li><li>â€¢ amiodarone, gemfibrozil, HIV</li><li>â€¢ protease inhibitors (such as saquinavir, ritonavir), and itraconazole.</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Which of the following statement is True regarding Sacubitril?", "options": [{"label": "A", "text": "It is a drug that can act by inhibiting angiotensin converting enzyme", "correct": false}, {"label": "B", "text": "It is a drug used in combination with valsartan for congestive heart failure", "correct": true}, {"label": "C", "text": "Hypokalemia is an adverse effect of sacubitril", "correct": false}, {"label": "D", "text": "Sacubitril is combined with ramipril for treatment of hypertension", "correct": false}], "correct_answer": "B. It is a drug used in combination with valsartan for congestive heart failure", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. B) It is a drug used in combination with valsartan for congestive heart failure</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>â€¢ Explanation:</li><li>â€¢ Option A. Incorrect because sacubitril is not an angiotensin converting enzyme (ACE) inhibitor , which typically have names ending in -pril.</li><li>â€¢ Option A.</li><li>â€¢ Incorrect</li><li>â€¢ sacubitril is not an angiotensin converting enzyme (ACE) inhibitor</li><li>â€¢ Option C. Incorrect as hypokalemia is not a side effect associated with sacubitril. It is more commonly associated with traditional diuretics rather than neprilysin inhibitors.</li><li>â€¢ Option C.</li><li>â€¢ Incorrect</li><li>â€¢ hypokalemia</li><li>â€¢ not a side effect</li><li>â€¢ sacubitril.</li><li>â€¢ more</li><li>â€¢ traditional</li><li>â€¢ diuretics</li><li>â€¢ neprilysin inhibitors.</li><li>â€¢ Option D. Incorrect because sacubitril is combined with valsartan, not ramipril , and the combination is used for heart failure, not specifically for hypertension.</li><li>â€¢ Option D.</li><li>â€¢ Incorrect</li><li>â€¢ sacubitril is combined with valsartan, not ramipril</li><li>â€¢ heart failure,</li><li>â€¢ Educational objective:</li><li>â€¢ Educational objective:</li><li>â€¢ Sacubitril is a neprilysin inhibitor used in combination with valsartan as an ARNI for the treatment of heart failure to reduce the risk of cardiovascular death and heart failure hospitalization , particularly in patients with reduced ejection fraction.</li><li>â€¢ Sacubitril is a neprilysin inhibitor</li><li>â€¢ with valsartan</li><li>â€¢ ARNI for the treatment of heart failure</li><li>â€¢ reduce the risk</li><li>â€¢ cardiovascular death and heart failure hospitalization</li><li>â€¢ reduced ejection fraction.</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Which of the following drugs is an oral renin inhibitor?", "options": [{"label": "A", "text": "Candesartan", "correct": false}, {"label": "B", "text": "Aliskiren", "correct": true}, {"label": "C", "text": "Quinapril", "correct": false}, {"label": "D", "text": "Benazepril", "correct": false}], "correct_answer": "B. Aliskiren", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. B) Aliskiren</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>â€¢ Explanation:</li><li>â€¢ Option A. Candesartan: Candesartan is an angiotensin II receptor blocker (ARB) . It works by blocking the action of angiotensin II at its receptor, preventing angiotensin II from causing vasoconstriction and aldosterone release, which in turn lowers blood pressure. It does not inhibit renin directly.</li><li>â€¢ Option A. Candesartan:</li><li>â€¢ angiotensin II receptor blocker (ARB)</li><li>â€¢ blocking the action of angiotensin II</li><li>â€¢ preventing angiotensin II</li><li>â€¢ vasoconstriction and aldosterone</li><li>â€¢ lowers blood pressure.</li><li>â€¢ does not inhibit renin</li><li>â€¢ Option C. Quinapril: Quinapril is an angiotensin-converting enzyme (ACE) inhibitor . It inhibits the enzyme responsible for converting angiotensin I to angiotensin II, a potent vasoconstrictor. By reducing the levels of angiotensin II, it lowers blood pressure. Quinapril acts later in the RAAS pathway compared to aliskiren and does not directly inhibit renin.</li><li>â€¢ Option C. Quinapril:</li><li>â€¢ angiotensin-converting enzyme (ACE) inhibitor</li><li>â€¢ converting</li><li>â€¢ angiotensin I to angiotensin II,</li><li>â€¢ potent vasoconstrictor.</li><li>â€¢ reducing</li><li>â€¢ angiotensin II,</li><li>â€¢ lowers blood pressure.</li><li>â€¢ RAAS pathway</li><li>â€¢ to aliskiren</li><li>â€¢ does not directly inhibit renin.</li><li>â€¢ Option D. Benazepril: Benazepril is also an ACE inhibitor, similar to quinapril. It lowers blood pressure by inhibiting the conversion of angiotensin I to angiotensin II, thereby reducing vasoconstriction and aldosterone-mediated volume expansion . Like quinapril, benazepril does not act by inhibiting renin.</li><li>â€¢ Option D. Benazepril:</li><li>â€¢ ACE inhibitor,</li><li>â€¢ quinapril.</li><li>â€¢ lowers blood pressure</li><li>â€¢ inhibiting</li><li>â€¢ conversion of</li><li>â€¢ angiotensin I to angiotensin II,</li><li>â€¢ reducing vasoconstriction</li><li>â€¢ aldosterone-mediated volume expansion</li><li>â€¢ quinapril,</li><li>â€¢ benazepril does not</li><li>â€¢ inhibiting renin.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>âž¤ Educational Objective:</li><li>âž¤ The objective is to understand the mechanisms of action of various drugs used in the management of hypertension, focusing on their roles within the renin-angiotensin-aldosterone system. Recognizing the unique action of aliskiren as a renin inhibitor, in contrast to ARBs and ACE inhibitors that act downstream, is essential for effective hypertension management.</li><li>âž¤ mechanisms of action</li><li>âž¤ management of hypertension,</li><li>âž¤ renin-angiotensin-aldosterone system.</li><li>âž¤ aliskiren as a renin inhibitor,</li><li>âž¤ contrast to ARBs and ACE inhibitors</li><li>âž¤ act downstream,</li><li>âž¤ hypertension management.</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Which of the following is the drug of choice for digoxin induced ventricular tachyarrhythmias?", "options": [{"label": "A", "text": "Quinidine", "correct": false}, {"label": "B", "text": "Amiodarone", "correct": false}, {"label": "C", "text": "Lignocaine", "correct": true}, {"label": "D", "text": "Phenytoin", "correct": false}], "correct_answer": "C. Lignocaine", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. C) Lignocaine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>â€¢ Explanation:</li><li>â€¢ Option A. Quinidine: Quinidine is an antiarrhythmic that can increase serum digoxin levels and is contraindicated in digoxin-induced arrhythmias because it may exacerbate toxicity.</li><li>â€¢ Option A. Quinidine:</li><li>â€¢ antiarrhythmic</li><li>â€¢ increase serum digoxin levels</li><li>â€¢ contraindicated in digoxin-induced arrhythmias</li><li>â€¢ exacerbate toxicity.</li><li>â€¢ Option B. Amiodarone: While amiodarone is a versatile antiarrhythmic agent used in various types of arrhythmias , it can interact with digoxin and increase its levels , potentially worsening toxicity.</li><li>â€¢ Option B. Amiodarone:</li><li>â€¢ versatile antiarrhythmic agent</li><li>â€¢ various types of arrhythmias</li><li>â€¢ interact</li><li>â€¢ digoxin and increase its levels</li><li>â€¢ worsening toxicity.</li><li>â€¢ Option D. Phenytoin: Phenytoin is effective for ventricular arrhythmias, especially in the context of acute myocardial infarction, but it is not the first choice for digoxin-induced arrhythmias. It can be used if lignocaine is not available or contraindicated.</li><li>â€¢ Option D. Phenytoin:</li><li>â€¢ ventricular arrhythmias,</li><li>â€¢ acute myocardial infarction,</li><li>â€¢ not the first choice for digoxin-induced arrhythmias.</li><li>â€¢ can be used</li><li>â€¢ lignocaine is not available or contraindicated.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>âž¤ Educational Objective:</li><li>âž¤ The educational goal is to understand the appropriate management of digoxin-induced ventricular tachyarrhythmias . Recognizing lignocaine as the drug of choice in this scenario is critical for effectively addressing the cardiac toxicity associated with digoxin overdose , minimizing the risk of further cardiac complications.</li><li>âž¤ appropriate management of digoxin-induced ventricular tachyarrhythmias</li><li>âž¤ lignocaine</li><li>âž¤ drug of choice</li><li>âž¤ critical for effectively addressing the cardiac toxicity</li><li>âž¤ digoxin</li><li>âž¤ overdose</li><li>âž¤ minimizing the risk</li><li>âž¤ cardiac complications.</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Ivabradine is a drug that has been used in clinical practice for few years now. It is indicated for the management of which of the following diseases?", "options": [{"label": "A", "text": "Stable angina", "correct": true}, {"label": "B", "text": "Prerenal azotemia", "correct": false}, {"label": "C", "text": "Alzheimerâ€™s disease", "correct": false}, {"label": "D", "text": "Smoking cessation", "correct": false}], "correct_answer": "A. Stable angina", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. A) Stable angina</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>â€¢ Explanation:</li><li>â€¢ Option B. Prerenal azotemia: Incorrect as prerenal azotemia is related to kidney function and ivabradine does not have a role in its treatment.</li><li>â€¢ Option B. Prerenal azotemia:</li><li>â€¢ Incorrect</li><li>â€¢ prerenal azotemia</li><li>â€¢ kidney function</li><li>â€¢ ivabradine does not</li><li>â€¢ treatment.</li><li>â€¢ Option C. Alzheimerâ€™s disease: Incorrect because Alzheimerâ€™s disease is a neurodegenerative condition and ivabradine is not indicated for its treatment.</li><li>â€¢ Option C. Alzheimerâ€™s disease:</li><li>â€¢ Incorrect</li><li>â€¢ neurodegenerative condition</li><li>â€¢ ivabradine is not</li><li>â€¢ treatment.</li><li>â€¢ Option D. Smoking cessation: Incorrect as ivabradine is not used in smoking cessation ; it is a cardiac medication used for heart rate control.</li><li>â€¢ Option D. Smoking cessation:</li><li>â€¢ Incorrect</li><li>â€¢ ivabradine</li><li>â€¢ not</li><li>â€¢ smoking cessation</li><li>â€¢ cardiac medication</li><li>â€¢ heart rate</li><li>â€¢ control.</li><li>â€¢ Educational objective:</li><li>â€¢ Educational objective:</li><li>â€¢ Ivabradine is indicated for the management of stable angina and congestive heart failure . It works by inhibiting the funny current in the SA node , leading to a reduction in heart rate, which is a key therapeutic target in managing these conditions.</li><li>â€¢ Ivabradine</li><li>â€¢ management of stable angina and congestive heart failure</li><li>â€¢ inhibiting the funny current</li><li>â€¢ SA node</li><li>â€¢ reduction in heart rate,</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Which of the following drug is used in CHF for relief of congestive symptoms and restoration of cardiac performance but does not possess inotropic action?", "options": [{"label": "A", "text": "Digoxin", "correct": false}, {"label": "B", "text": "Dobutamine", "correct": false}, {"label": "C", "text": "Amrinone", "correct": false}, {"label": "D", "text": "Metoprolol", "correct": true}], "correct_answer": "D. Metoprolol", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. D) Metoprolol</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>â€¢ Explanation:</li><li>â€¢ Option A. Digoxin: Digoxin has a positive inotropic effect , increasing the force of cardiac contractions , and is used in CHF to improve symptoms and cardiac performance. It does not fit the criteria as it possesses inotropic action.</li><li>â€¢ Option A. Digoxin:</li><li>â€¢ positive inotropic effect</li><li>â€¢ increasing the force of cardiac contractions</li><li>â€¢ CHF to improve</li><li>â€¢ symptoms and cardiac performance.</li><li>â€¢ does not</li><li>â€¢ inotropic action.</li><li>â€¢ Option B. Dobutamine: Dobutamine is a beta-1 adrenergic agonist with positive inotropic effects , used primarily in acute heart failure to increase cardiac output. It directly increases the force of heart contractions.</li><li>â€¢ Option B. Dobutamine:</li><li>â€¢ beta-1 adrenergic agonist</li><li>â€¢ positive inotropic effects</li><li>â€¢ acute heart</li><li>â€¢ failure</li><li>â€¢ increase cardiac output.</li><li>â€¢ increases the force of heart contractions.</li><li>â€¢ Option C. Amrinone: Amrinone is a phosphodiesterase inhibitor with positive inotropic and vasodilatory effects , used to improve cardiac output in heart failure patients. Like dobutamine and digoxin, it increases the force of cardiac contractions.</li><li>â€¢ Option C. Amrinone:</li><li>â€¢ phosphodiesterase inhibitor</li><li>â€¢ positive inotropic and vasodilatory effects</li><li>â€¢ improve</li><li>â€¢ cardiac output</li><li>â€¢ dobutamine and digoxin,</li><li>â€¢ increases the force of cardiac contractions.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>âž¤ Educational Objective:</li><li>âž¤ The educational goal is to understand the role of different classes of drugs in the management of CHF, particularly distinguishing those with and without inotropic action. Metoprolol